tiprankstipranks
Halozyme Therapeutics (DE:RV7)
:RV7

Halozyme (RV7) Price & Analysis

Compare
3 Followers

RV7 Stock Chart & Stats


---

Bulls Say, Bears Say

Bulls Say
Financial GuidanceHalozyme issued updated 2025-2028 financial guidance above its previous guidance, driven by strong VYVGART Hytrulo, Darzalex SC and Phesgo momentum plus out-year benefits from recently approved products.
Market PotentialThe ENHANZE platform enables under-the-skin administration of traditionally IV-administered drugs, significantly improving convenience and potentially capturing a large portion of the expanding U.S. infusion therapy market.
Regulatory ApprovalThe European regulatory agency CHMP has issued a positive opinion for Janssen's subcutaneous Rybrevant in combination with Halozyme’s Enhanze for patients with advanced non-small cell lung cancer.
Bears Say
Commercial RiskRisks include commercial risk with Enhanze, failure to generate favorable clinical data from ongoing programs, partnership risk, and possible long-term dilution risk.
Manufacturing IssuesJanssen, a J&J subsidiary, is working with the FDA to resolve manufacturing issues cited by a letter from the agency in December 2024.
Revenue GuidanceThe company assumes no milestone revenue in the first half and expects $100M-$130M in collaboration revenue for the full year, which is roughly $30M lower than the previous guidance due to the amivantamab CRL.
---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

0.99%31.20%0.54%36.93%
0.54% Other Institutional Investors
36.93% Public Companies and Individual Investors

RV7 FAQ

What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was €32.19 and its highest was €58.18 in the past 12 months.
    What is Halozyme Therapeutics’s market cap?
    Halozyme Therapeutics’s market cap is €7.11B.
      When is Halozyme Therapeutics’s upcoming earnings report date?
      Halozyme Therapeutics’s upcoming earnings report date is Feb 18, 2025 which is in 4 days.
        How were Halozyme Therapeutics’s earnings last quarter?
        Halozyme Therapeutics released its earnings results on Oct 31, 2024. The company reported €1.233 earnings per share for the quarter, beating the consensus estimate of €0.962 by €0.271.
          Is Halozyme Therapeutics overvalued?
          According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Halozyme Therapeutics pay dividends?
            Halozyme Therapeutics does not currently pay dividends.
            What is Halozyme Therapeutics’s EPS estimate?
            Halozyme Therapeutics’s EPS estimate is 1.08.
              How many shares outstanding does Halozyme Therapeutics have?
              Halozyme Therapeutics has 127,227,000 shares outstanding.
                What happened to Halozyme Therapeutics’s price movement after its last earnings report?
                Halozyme Therapeutics reported an EPS of €1.233 in its last earnings report, beating expectations of €0.962. Following the earnings report the stock price went up 12.019%.
                  Which hedge fund is a major shareholder of Halozyme Therapeutics?
                  Currently, no hedge funds are holding shares in DE:RV7
                  ---

                  Company Description

                  Halozyme Therapeutics

                  Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
                  ---

                  RV7 Company Deck

                  ---

                  RV7 Earnings Call

                  Q3 2024
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The earnings call was largely positive, highlighting record revenue growth, successful new partnerships and approvals, and a positive outlook with increased guidance. A few challenges were noted, particularly around the MDASE platform and product sales fluctuations, but these were outweighed by the positive developments.Read More>
                  ---

                  RV7 Revenue Breakdown

                  54.01%54.01%36.28%9.71%
                  54.01% Royalties
                  36.28% Product sales
                  9.71% Revenues under collaborative agreements
                  tipranks
                  ---

                  RV7 Stock 12 Month Forecast

                  Average Price Target

                  €61.91
                  ▲(11.83% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"€30","41":"€41","52":"€52","63":"€63","74":"€74"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":73.62242426,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€73.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.909765855,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€61.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.67517514,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€50.68</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,41,52,63,74],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Nov<br/>2024","12":"Feb<br/>2025","25":"Feb<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.36,55.841724943076926,57.323449886153846,58.80517482923077,60.28689977230769,61.76862471538462,63.25034965846154,64.73207460153846,66.21379954461538,67.69552448769231,69.17724943076924,70.65897437384615,72.14069931692308,{"y":73.62242426,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.36,54.940751219615386,55.52150243923077,56.10225365884615,56.68300487846154,57.263756098076925,57.84450731769231,58.42525853730769,59.00600975692308,59.586760976538464,60.16751219615385,60.74826341576923,61.32901463538462,{"y":61.909765855,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.36,54.076551933846154,53.79310386769231,53.509655801538464,53.22620773538461,52.94275966923077,52.65931160307692,52.37586353692308,52.09241547076923,51.80896740461539,51.525519338461535,51.24207127230769,50.958623206153845,{"y":50.67517514,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.2,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.69,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.37,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.04,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.55,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.56,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Amgen
                  Biogen
                  Gilead Sciences
                  Regeneron
                  Vertex Pharmaceuticals

                  Best Analysts Covering RV7

                  1 Year
                  Mitchell KapoorH.C. Wainwright
                  Not Ranked
                  1 Year Success Rate
                  16/19 ratings generated profit
                  84%
                  1 Year Average Return
                  +23.68%
                  reiterated a buy rating 11 days ago
                  Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +23.68% per trade.
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis